Cipla Director Vikram Janakiraman appointed
Cipla (CIPLA) said Vikram Janakiraman, Director, has been appointed. The company is valued at about ₹1.13 lakh crore.
What happened
Cipla (CIPLA) told the exchanges on 4 November 2026 at 03:10 PM that Vikram Janakiraman, Director, has been appointed.
Company snapshot
Cipla is a large-cap company in the Healthcare sector, with a market value of about ₹1.13 lakh crore.
The stock last traded at ₹1,396.9, against a 52-week range of ₹1,165.7–₹1,539.7 (9.3% below the high).
Before this filing the shares had moved +3.9% over the month and −4.3% over three months. Average daily turnover over the last 20 sessions was about ₹161 crore.
Promoters held 29.21% at the end of Q2 FY27. Foreign institutions owned 20.25% and domestic institutions 34.94%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 7,589 | 1,351.2 | 16.73 |
| Q3 FY26 | 7,074 | 675.8 | 8.37 |
| Q4 FY26 | 6,541 | 554.6 | 6.87 |
| Q1 FY27 | 7,119 | 789.1 | 9.77 |
| Q2 FY27 | 7,404 | 877.5 | 10.86 |
What history shows
BCEIE's records show 7 previous management change filings from the company since May 2026.
After those filings, the stock gained 0.4% on average the next trading day and was up 3.5% on average after five days (5 filings with price data).
Across 117 similar disclosures by other Healthcare companies, shares moved +1.0% on average the next day and +1.7% over five days; 48% of them rose the next day.
Market-wide, 4,237 management change filings with an impact score of 50 or more saw an average next-day move of −0.1%, with 44% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 27 Oct 2026 | Appointment of Ms Rashmi Joshi as Independent Director of the… | +0.8% | +3.1% |
| 22 Sept 2026 | Change in Senior Management Personnel. | +1.1% | — |
| 23 Jul 2026 | Management change | +1.2% | +5.8% |
| 25 Jun 2026 | Change in Auditors of the company. | +1.0% | +1.3% |
What to watch
- The appointment of a successor and any change in strategy or guidance.
In the news
Recent coverage elsewhere (links open the original publisher):
- Indian drugmaker Cipla misses profit view on US weakness, shares slip
- Cipla Q2 results: Net profit plunges 35% to Rs 878 crore, revenue down 2.4% YoY; stock falls
- CIPLA Share Price Today - Cipla on NSE/BSE
- Earnings Central: L&T, Bajaj Auto, Maruti Suzuki, Cipla headline Tuesday’s Q2 results
- Cipla Q2 profit falls 35 per cent to ₹878 crore as revenue declines 2 per cent
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.